(S)-ethylmalonyl-CoA

An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with one of the carboxy groups of (2S)-ethylmalonic acid.


The S-3-hydroxy-3-(4-methylpent-3-en-1-yl)glutaryl derivative of CoA.


decanedioyl-CoA

An alpha,omega dicarboxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with one of the carboxy groups of decanedioic acid.


adipoyl-CoA

An alpha,omega dicarboxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with one of the carboxy groups of adipic acid.


A 3-hydroxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the 3-carboxy group of 3-carboxy-3-hydroxypropanoic acid.


octanedioyl-CoA

An alpha,omega dicarboxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with one of the carboxy groups of octanedioic acid.


A 3-hydroxy-3-methylglutaryl-CoA where the 3-hydroxy-3-methylglutaryl component has (S)-configuration.


glutaryl-CoAs

Any  omega-carboxyacyl-CoA in which the acyl group specified is glutaryl or its substituted derivative.


An alpha,omega dicarboxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with one of the carboxy groups of 3-hydroxy-3-methylglutaric acid.


glutaryl-CoA

An omega-carboxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with one of the carboxy groups of glutaric acid.


dodecanedioyl-CoA

An alpha,omega dicarboxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with one of the carboxy groups of dodecanedioic acid.


Intermediate Grade Osteosarcoma

category: biolink:Disease biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

description: An osteosarcoma with intermediate-grade morphological features. A representative example is periosteal osteosarcoma.


name: Peripheral Nervous System Infectious Disorder

description: An infectious process affecting the peripheral nerves.


A glycosylmannose consisting of two D-mannopyranose residues joined via an alpha-(1->3)-linkage.


name: (6S)-6-hydroxy-1,4,5,6-tetrahydronicotinamide adenine dinucleotide 2'-phosphate


name: tetrahydronicotinamide adenine dinucleotide phosphate

description: A nicotinamide dinucleotide having any tetrahydronicotinamide and adenosine as the nucleobases as well as an additional phosphate group.


B-Cell Malignant Neoplasm

description: A clonal lymphoproliferative disorder composed of neoplastic B-cells. It includes B-cell non-Hodgkin lymphomas, B-cell leukemias, and plasma cell myeloma.


Chronic lymphocytic leukemia stage 1

description: Risk: Intermediate; Findings: Lymphocytosis and adenopathy; Survival (months): 95. (from AJCC 8th Ed.)


name: Multiple Myeloma with MAF Family Translocation

description: Multiple myeloma characterized by the presence of a translocation involving a MAF family gene.


DS Stage IA Multiple Myeloma

description: Durie/Salmon stage I multiple myeloma associated with a relatively normal renal function (serum creatinine concentration < 2.0 mg/dL).


name: B Acute Lymphoblastic Leukemia with t(4;11)(q21;23.3); KMT2A-AFF1

description: A B-cell acute lymphoblastic leukemia associated with t(4;11)(q21;23.3). This translocation leads to the generation of the fusion gene KMT2A-AFF1.


name: Childhood B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1

description: A B acute lymphoblastic leukemia that occurs during childhood. It is characterized by the presence of lymphoblasts that carry a translocation between the BCR gene on chromosome 22 and the ABL1 gene on chromosome 9. It results in the production of the p190 kd or p210 kd fusion protein. It has an unfavorable clinical outcome.


name: Hypodiploid B Acute Lymphoblastic Leukemia

description: A B-cell acute leukemia characterized by the presence of lymphoblasts which contain less than 46 chromosomes. It occurs in both children and adults. It has an unfavorable clinical outcome.


Recurrent Chronic Lymphoid Leukemia

description: The reemergence of chronic lymphocytic leukemia after a period of remission.


name: Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

description: Chronic lymphocytic leukemia/small lymphocytic lymphoma that does not respond to treatment.


name: Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

description: The reemergence of chronic lymphocytic leukemia/small lymphocytic lymphoma after a period of remission.


name: Refractory B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1

description: B-acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 that is resistant to treatment.


Leptomeningeal myelomatosis

description: A central nervous system multiple myeloma involving the leptomeninges.


name: B Acute Lymphoblastic Leukemia with Recurrent Genetic Abnormalities

description: B-acute lymphoblastic leukemias characterized by the presence of recurring cytogenetic and/or molecular abnormalities.


name: Refractory B Acute Lymphoblastic Leukemia

description: B-acute lymphoblastic leukemia that does not respond to treatment.


Plasma cell myeloma recurrent

description: The reemergence of multiple myeloma after a period of remission.


DS Stage IIIB Multiple Myeloma

description: Durie/Salmon stage III multiple myeloma associated with abnormal renal function (serum creatinine concentration greater than or equal to 2.0 mg/dL).


name: Recurrent B Acute Lymphoblastic Leukemia, BCR-ABL1-Like

description: The reemergence of  B-acute lymphoblastic leukemia, BCR-ABL1-like after a period of remission.


name: B Acute Lymphoblastic Leukemia with ETV6-RUNX1-Like Features

description: B acute lymphoblastic leukemia characterized by a gene-expression profile similar to that of ETV6-RUNX1-positive B acute lymphoblastic leukemia, absence of the pathognomonic ETV6-RUNX1 rearrangement, and rearrangements or deletions of ETV6 and IKZF1 genes.


name: Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder

description: A clonal B-cell lymphoproliferative disorder arising as a result of post-transplant immunosuppression therapy. It is characterized by destructive infiltration of lymph nodes and extranodal sites by a monotonous population of transformed B-lymphocytes or plasma cells. The clonal cellular infiltrates fulfill the criteria for a diffuse large B-cell lymphoma, Burkitt lymphoma, or a plasma cell neoplasm.


name: Recurrent B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

description: The reemergence of B acute lymphoblastic leukemia, Philadelphia chromosome negative, after a period of remission.


name: Multiple Myeloma, Not Otherwise Specified

description: Multiple myelomas characterized by the absence of recurrent genetic abnormalities.


name: B Acute Lymphoblastic Leukemia, Not Otherwise Specified

description: B-acute lymphoblastic leukemias characterized by the absence of recurrent genetic abnormalities.


name: Extramedullary Disease in Multiple Myeloma Involving the Central Nervous System

description: Multiple myeloma involving the central nervous system. It manifests with single or multiple intraparenchymal lesions and/or leptomeningeal involvement. Patients present with diffuse cerebral dysfunction and nerve paralysis. The prognosis is poor.


Stage A Chronic Lymphocytic Leukemia

description: Findings: Lymphocytosis only; Survival (months): more than 120. (from AJCC 8th Ed.)


name: Chronic Lymphocytic Leukemia with Unmutated Immunoglobulin Heavy Chain Variable-Region Gene

description: Chronic lymphocytic leukemia characterized by the absence of somatic hypermutation within the immunoglobulin heavy chain gene variable region of neoplastic clones. Patients have a significantly worse prognosis as compared to those with mutated immunoglobulin heavy chain gene variable region rearrangements.


name: B Acute Lymphoblastic Leukemia with Mutated ZEB2 (p.H1038R)

description: B-acute lymphoblastic leukemia associated with mutations in the ZEB2 gene that encode a histidine to arginine amino acid substitution at codon 1038. This variation appears to phenocopy the IGH-CEBPE gene fusion. This is a provisional entity.


name: Refractory B-Cell Prolymphocytic Leukemia

description: B-cell prolymphocytic leukemia that is resistant to treatment.


name: Chronic Lymphocytic Leukemia- Binet Staging System

description: A term that refers to the staging of chronic lymphocytic leukemia according to Binet staging system. This system is in wide use outside the United States.


Chronic lymphocytic leukemia stage 4

description: Risk: High; Findings: Lymphocytosis and platelets less than 100,000/microliter; Survival (months): 30. (from AJCC 8th Ed.)


name: Cutaneous B Lymphoblastic Leukemia/Lymphoma

description: B-lymphoblastic leukemia/lymphoma that affects the skin.


Recurrent Extraosseous Plasmacytoma

description: The reemergence of extraosseous plasmacytoma after a period of remission.


Recurrent Solitary Plasmacytoma

description: The reemergence of solitary plasmacytoma after a period of remission.


Stage B Chronic Lymphocytic Leukemia

description: Findings: Lymphocytosis and adenopathy; Survival (months): 95. (from AJCC 8th Ed.)


name: Multiple Myeloma Post-Transplant Lymphoproliferative Disorder

description: A lymphoproliferative disorder that develops following an organ transplantation and exhibits multiple myeloma features.


name: Multiple Myeloma with Recurrent Genetic Abnormalities

description: Multiple myelomas characterized by the presence of recurring cytogenetic abnormalities.


name: Plasmacytoma-Like Post-Transplant Lymphoproliferative Disorder

description: A plasmacytoma-like hematologic malignancy that arises in a patient with a history of organ transplantation.


name: B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 with Multilineage Involvement

description: B-acute lymphoblastic leukemia associated with t(9;22)(q34.1;q11.2); BCR-ABL1 and characterized by both lymphoblastic and differentiating myeloid cell proliferation.


name: B Acute Lymphoblastic Leukemia with Germline IKZF1 Mutation

description: B-acute lymphoblastic leukemia that results from germline mutation of the IKZF1 gene.


Chronic lymphocytic leukemia stage 2

description: Risk: Intermediate; Findings: Lymphocytosis, adenopathy, and enlarged spleen and/or liver; Survival (months): 72. (from AJCC 8th Ed.)


name: Adult B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1

description: A B acute lymphoblastic leukemia that occurs during adulthood. It is characterized by the presence of lymphoblasts that carry a translocation between the BCR gene on chromosome 22 and the ABL1 gene on chromosome 9. It results in the production of the p190 kd or p210 kd fusion protein. It has an unfavorable clinical outcome.


Refractory B-Cell Malignant Neoplasm

description: A B-cell malignant neoplasm that is resistant to treatment.


name: Multiple Myeloma with CCND Family Translocation

description: Multiple myeloma characterized by the presence of a translocation involving a CCND family gene.


RISS Stage I Multiple Myeloma

description: Serum beta-2-microglobulin less than 3.5 mg/L and serum albumin 3.5 g/dL or more and no high-risk cytogenetics and normal LDH. High risk cytogenetics consist of one or more of the following: del17p, t(4;14), or t(14;16). (from AJCC 8th Ed.)


DS Stage IIB Multiple Myeloma

description: Durie/Salmon stage II multiple myeloma associated with abnormal renal function (serum creatinine concentration greater than or equal to 2.0 mg/dL).


name: Chronic Lymphocytic Leukemia with Plasmacytoid Differentiation

description: A chronic lymphocytic leukemia characterized by the presence of neoplastic lymphocytes with plasmacytoid morphology.


name: Near-Haploid B Acute Lymphoblastic Leukemia

description: B-acute lymphoblastic leukemia associated with a near haploid karyotype.


name: B Acute Lymphoblastic Leukemia with IKZF1 N159Y Mutation

description: B-acute lymphoblastic leukemia associated with IKZF1 missense mutation p.Asn159Tyr (N159Y).


name: B Acute Lymphoblastic Leukemia with UBTF-ATXN7L3/PAN3, CDX2 ("CDX2/UBTF")

description: B-acute lymphoblastic leukemia associated with concomitant CDX2 deregulation and expression of the chimeric UBTF-ATXN7L3 fusion oncoprotein. It usually affects female adolescents and young adults. The prognosis is poor following treatment with conventional chemotherapy.


name: Extramedullary Disease in Plasma Cell Myeloma

description: Infiltration of organs and soft tissues by malignant (clonal) plasma cells in patients with history of multiple myeloma. Skin, liver, lymph nodes, pleura, and central nervous system are the most frequently affected sites.


Head and Neck Plasmacytoma

description: A plasmacytoma that arises from the head and neck region.


Sinonasal Plasmacytoma

description: A plasmacytoma that arises from the sinonasal tract.


DS Stage IIA Multiple Myeloma

description: Durie/Salmon stage II multiple myeloma associated with a relatively normal renal function (serum creatinine concentration < 2.0 mg/dL).


name: Progressive Hairy Cell Leukemia Initial Treatment

description: A hairy cell leukemia requiring initial treatment because of the presence of signs of progression.  Signs of progression include cytopenia (especially if symptomatic), increasing splenomegaly, and infectious complications.  Therapy is not necessary if the patients are asymptomatic and the blood counts are maintained in an acceptable range.


name: Refractory Transformed Chronic Lymphocytic Leukemia

description: Chronic lymphocytic leukemia which has undergone histologic transformation to an aggressive diffuse large B-cell lymphoma (Richter's transformation) and has become resistant to treatment.


name: B Lymphoblastic Leukemia/Lymphoma with MYC Rearrangement

description: B-lymphoblastic leukemia/lymphoma associated with MYC gene rearrangement. The prognosis is poor.


Primary cutaneous plasmacytoma

description: A plasmacytoma that arises in the skin.


name: B Acute Lymphoblastic Leukemia with PAX5 Alteration

description: B-acute lymphoblastic leukemia associated with PAX5 gene alteration, including rearrangements, point mutations, and intragenic lesions. This is a provisional entity.


name: B Lymphoblastic Leukemia/Lymphoma with TCF3-HLF Rearrangement

description: An exceptionally rare childhood B-lymphoblastic leukemia/lymphoma associated with TCF3-HLF gene rearrangement resulting in the formation of TCF3-HLF chimeric transcription factor. The prognosis is poor.


name: B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, JAK-STAT Activated

description: B-acute lymphoblastic leukemia, BCR-ABL1-like associated with aberrant activation of the JAK-STAT signaling pathway.


name: Chronic Lymphocytic Leukemia with Immunoglobulin Heavy Chain Variable-Region Gene Somatic Hypermutation

description: Chronic lymphocytic leukemia characterized by the presence of somatic hypermutation within the immunoglobulin heavy chain gene variable region of neoplastic clones. Patients have a better prognosis as compared to those with unmutated immunoglobulin heavy chain gene variable region rearrangements.


Plasma cell myeloma refractory

description: Multiple myeloma that is resistant to treatment.


Testicular Plasmacytoma

description: A rare plasmacytoma that arises in the testis. At presentation the involvement is usually unilateral.


name: B Acute Lymphoblastic Leukemia with Germline PAX5 Mutation

description: B-acute lymphoblastic leukemia that results from germline mutation of the PAX5 gene.


DS Stage II Plasma Cell Myeloma

description: Multiple myeloma that fits in neither stage I nor stage III.  Estimated myeloma cell mass: 0.6 to 1.2 trillion (1012)/m2 (intermediate burden).  The following subclassification of stages is used: a. Creatinine less than 2.0 mg/dL, b. Creatinine greater than or equal to 2.0 mg/dL.  Impaired renal function worsens prognosis regardless of stage.  Note that the newer International Staging System defines stage II quite differently: Beta-2-microglobulin less than 3.5 and albumin less than 3.5 or beta-2-microglobulin 3.5 to less than 5.5 (median survival of 44 months).  (PDQ)


name: B Acute Lymphoblastic Leukemia with MEF2D Rearrangement

description: B-acute lymphoblastic leukemia associated with MEF2D gene rearrangement. The prognosis is poor.


Chronic lymphocytic leukemia refractory

description: Chronic lymphocytic leukemia that is resistant to treatment.


name: Transformed Chronic Lymphocytic Leukemia to Hodgkin Lymphoma

description: Histologic transformation of chronic lymphocytic leukemia to Hodgkin lymphoma.


name: Recurrent B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1

description: The reemergence of B acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 after a period of remission.


name: Extramedullary Disease in Multiple Myeloma Involving the Uterine Corpus

description: Infiltration of the uterine corpus by malignant (clonal) plasma cells in patients with history of multiple myeloma.


name: Childhood B Lymphoblastic Leukemia/Lymphoma

description: B lymphoblastic leukemia/lymphoma that occurs during childhood.


Multiple Myeloma with t(11;14)(q13;q32)

description: Multiple myeloma characterized by the presence of t(11;14)(q13;q32). It is the most common immunoglobulin heavy chain translocation found in multiple myeloma and results in CCND1 overexpression.


name: B Acute Lymphoblastic Leukemia, BCR-ABL1-Like

description: B acute lymphoblastic leukemia characterized by a gene-expression profile similar to that of BCR-ABL1-positive B acute lymphoblastic leukemia, absence of the pathognomonic BCR-ABL1 rearrangement, alterations of lymphoid transcription factor genes, and a poor outcome.


name: B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, ABL1 Rearranged

description: B-acute lymphoblastic leukemia, BCR-ABL1-like associated with ABL1 gene rearrangement.


name: Chronic Lymphocytic Leukemia- Modified Rai Staging System

description: A term that refers to the staging of chronic lymphocytic leukemia according to modified Rai staging system. This system is mainly used in North America.


Chronic lymphocytic leukemia stage 3

description: Risk: High; Findings: Lymphocytosis and hemoglobin less than 11 g/dL; Survival (months): 30. (from AJCC 8th Ed.)


RISS Stage II Multiple Myeloma

description: Not stage I or III. (from AJCC 8th Ed.)


name: Low-Hypodiploid B Acute Lymphoblastic Leukemia

description: B-acute lymphoblastic leukemia associated with a low hypodiploid karyotype.


Multiple Myeloma by ISS Stage

description: A header term that refers to the staging of multiple myeloma according to the International Staging System.


Recurrent Burkitt Leukemia

description: The reemergence of Burkitt leukemia after a period of remission.


name: Plasma Cell Post-Transplant Lymphoproliferative Disorder

description: A plasma cell neoplasm that arises in a patient with a history of organ transplantation.


Multiple Myeloma by RISS Stage

description: A staging system for multiple myeloma based on the Revised International Staging System (RISS) criteria. This staging system does not apply to smoldering multiple myeloma (no AJCC staging system), monoclonal gammopathy of undetermined significance (no AJCC staging system), and Waldenstrom macroglobulinemia (no AJCC staging system). (from AJCC 8th Ed.)


name: B Acute Lymphoblastic Leukemia with Germline Predisposition

description: B-acute lymphoblastic leukemia that results from germline gene mutations. This category includes B-acute lymphoblastic leukemia with germline PAX5 mutation and B-acute lymphoblastic leukemia with germline IKZF1 mutation.


Adult Burkitt Leukemia

description: The leukemic counterpart of Burkitt lymphoma occurring in adults.  The characteristic Burkitt cells are seen in the bone marrow and the peripheral blood.  This is an aggressive leukemia.


ISS Stage II Plasma Cell Myeloma

description: Multiple myeloma with blood levels of beta-2-microglobulin between 3.5 and 5.5 mg/L.


Recurrent B-Cell Malignant Neoplasm

description: The reemergence of a B-cell malignant neoplasm after a period of remission.


Plasmacytoma anaplastic

description: A plasmacytoma characterized by the presence of malignant plasma cells with anaplastic features.


name: B Acute Lymphoblastic Leukemia with MYC Rearrangement

description: B-acute lymphoblastic leukemia associated with MYC gene rearrangement. The prognosis is poor.


Refractory Burkitt Leukemia

description: Burkitt leukemia resistant to treatment.


name: Multiple Myeloma with NSD2 Translocation

description: Multiple myeloma characterized by the presence of a translocation involving the NSD2 gene.


name: Recurrent Transformed Chronic Lymphocytic Leukemia

description: The reemergence of chronic lymphocytic leukemia transformed to aggressive diffuse large B-cell lymphoma (Richter's transformation) after a period of remission.


name: Extramedullary Disease in Multiple Myeloma Involving the Skin

description: Infiltration of the skin by malignant (clonal) plasma cells in patients with history of multiple myeloma.


Advanced B-Cell Malignant Neoplasm

description: A B-cell malignant neoplasm that has spread extensively to other anatomic sites or is no longer responding to treatment.


name: B Acute Lymphoblastic Leukemia with ZNF384 Rearrangement

description: B-acute lymphoblastic leukemia associated with ZNF384 gene rearrangement. The prognosis is variable.


name: B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 with Lymphoid Only Involvement

description: B-acute lymphoblastic leukemia associated with t(9;22)(q34.1;q11.2); BCR-ABL1 and characterized by lymphoblastic proliferation without differentiating myeloid cell proliferation.


Stage C Chronic Lymphocytic Leukemia

description: Findings: Lymphocytosis, adenopathy, and enlarged spleen and/or liver; Survival (months): 72. (from AJCC 8th Ed.)


Cutaneous Chronic Lymphocytic Leukemia

description: A chronic lymphocytic leukemia that affects the skin.


DS Stage III Plasma Cell Myeloma

description: Multiple myeloma with one or more of the following: 1. Hemoglobin less than 8.5 g/dL. 2. Serum calcium greater than 12.0 mg/dL. 3. More than three lytic bone lesions. 4. High M protein production as shown by: a. IgG greater than 7.0 g/dL. b. IgA greater than 5.0 g/dL. c. Urinary kappa or lamda greater than 12.0 g/24 hours. Estimated myeloma cell mass: greater than 1.2 trillion (1012)/m2 (high burden). The following subclassification of stages is used: a. Creatinine less than 2.0 mg/dL. b. Creatinine greater than or equal to 2.0 mg/dL. Serum beta-2-microglobulin has been shown to be a reliable marker for prognosis. Since the great majority of symptomatic myeloma patients are classified as stage III by the Durie/Salmon criteria, this staging system has not proven to be very useful for identifying the patients with intermediate and poor prognosis. Note that the newer International Staging System defines stage III quite differently: Beta-2-microglobulin greater than or equal to 5.5 (median survival of 29 months). (PDQ)


DS Stage I Plasma Cell Myeloma

description: Multiple myeloma with all of the following: 1. Hemoglobin greater than 10 g/Dl, 2. Normal serum calcium, 3. Normal bone structure, 4. Low monoclonal (or myeloma) protein (M protein) production as shown by: a. IgG less than 5.0 g/dL, b. IgA less than 3.0 g/dL, c. Urinary kappa or lamda less than 4 g/24 hours. Estimated myeloma cell mass: less than 0.6 trillion (1012)/m2 (low burden). The following subclassification of stages is used: a. Creatinine less than 2.0 mg/dL, b. Creatinine greater than or equal to 2.0 mg/dL. Impaired renal function worsens prognosis regardless of stage. Note that the newer International Staging System defines stage I quite differently: Beta-2-microglobulin less than 3.5 and albumin greater than or equal to 3.5 (median survival of 62 months). (PDQ)


name: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

description: A B-acute lymphoblastic leukemia (B-ALL) that does not have the cytogenetic abnormality t(9;22)(q34;q11.2). Most cases of B-ALL do not have this translocation.


DS Stage IIIA Multiple Myeloma

description: Durie/Salmon stage III multiple myeloma associated with a relatively normal renal function (serum creatinine concentration < 2.0 mg/dL).


name: B Lymphoblastic Leukemia/Lymphoma with ETV6-RUNX1-Like Features

description: B lymphoblastic leukemia/lymphoma characterized by a gene-expression profile similar to that of ETV6-RUNX1-positive B lymphoblastic leukemia/lymphoma, absence of the pathognomonic ETV6-RUNX1 rearrangement, and rearrangements or deletions of ETV6 and IKZF1 genes.


name: Recurrent B Acute Lymphoblastic Leukemia

description: The reemergence of B acute lymphoblastic leukemia after a period of remission.


RISS Stage III Multiple Myeloma

description: Serum beta-2-microglobulin 5.5 mg/L or more and high-risk cytogenetics and/or high LDH. High risk cytogenetics consist of one or more of the following: del17p, t(4;14), or t(14;16). (from AJCC 8th Ed.)


name: B Acute Lymphoblastic Leukemia Associated with Down Syndrome

description: A B-acute lymphoblastic leukemia that occurs in patients with Down syndrome. It usually affects young children, but it can occur in adults as well. It has an unfavorable clinical outcome. Cases of T-acute lymphoblastic leukemia in patients with Down syndrome have not been reported.


name: Hyperdiploid B Acute Lymphoblastic Leukemia

description: A B-cell acute leukemia characterized by the presence of lymphoblasts which contain more than 50 and usually less than 66 chromosomes. It is commonly seen in children and rarely in adults. It has a favorable clinical outcome.


name: B Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified

description: B-lymphoblastic leukemias/lymphomas characterized by the absence of recurrent genetic abnormalities.


name: B Acute Lymphoblastic Leukemia with NUTM1 Rearrangement

description: B-acute lymphoblastic leukemia associated with NUTM1 gene rearrangement. The prognosis is good.


ISS Stage III Plasma Cell Myeloma

description: Multiple myeloma with beta-2-microglobulin greater than or equal to 5.5 (median survival of 29 months).  Note that the older Durie/Salmon staging system defines stage III quite differently. (PDQ)


DS Stage IB Multiple Myeloma

description: Durie/Salmon stage I multiple myeloma associated with abnormal renal function (serum creatinine concentration greater than or equal to 2.0 mg/dL).


name: B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, ABL Class Rearranged

description: B-acute lymphoblastic leukemia, BCR-ABL1-like associated with rearrangement of an ABL class gene (e.g., ABL1, ABL2, CSF1R, PDGFRA, and PDGFRB).


name: Recurrent B-Cell Prolymphocytic Leukemia

description: The reemergence of a B-cell prolymphocytic leukemia after a period of remission.


name: Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma

description: Histologic transformation of an indolent chronic lymphocytic leukemia to an aggressive diffuse large B-cell lymphoma.


name: Extramedullary Disease in Multiple Myeloma Involving the Kidney

description: Infiltration of the kidney by malignant (clonal) plasma cells in patients with history of multiple myeloma.


Multiple Myeloma with Hyperdiploidy

description: Multiple myeloma characterized by the presence of plasma cells in which the chromosomal number is greater than the normal diploid number.


Chronic lymphocytic leukemia stage 0

description: Risk: Low; Findings: Lymphocytosis only; Survival (months): more than 120. (from AJCC 8th Ed.)


name: Refractory B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

description: B acute lymphoblastic leukemia, Philadelphia chromosome negative, that does not respond to treatment.


name: B Acute Lymphoblastic Leukemia with ZNF362 Rearrangement

description: B-acute lymphoblastic leukemia associated with ZNF362 gene rearrangement. The prognosis is variable.


name: Refractory B Acute Lymphoblastic Leukemia, BCR-ABL1-Like

description: B-acute lymphoblastic leukemia, BCR-ABL1-like that does not respond to treatment.


ISS Stage I Plasma Cell Myeloma

description: Multiple myeloma with beta-2-microglobulin less than 3.5 and albumin greater than or equal to 3.5 (median survival of 62 months).  Note that the older Durie/Salmon staging system defines stage I quite differently. (PDQ)


name: B-lymphoblastic leukemia lymphoma BCR-ABL1-like

description: B lymphoblastic leukemia/lymphoma characterized by a gene-expression profile similar to that of BCR-ABL1-positive B lymphoblastic leukemia/lymphoma, absence of the pathognomonic BCR-ABL1 rearrangement, alterations of lymphoid transcription factor genes, and a poor outcome.


name: B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Not Otherwise Specified

description: B-acute lymphoblastic leukemia, BCR-ABL1-like in which further genetic/molecular characterization is not available.


Multiple Myeloma Myeloma by DS Stage

description: A header term that refers to the staging of multiple myeloma according to the Durie/Salmon staging system.


Childhood Burkitt Leukemia

description: The leukemic counterpart of Burkitt lymphoma occurring in children.  The characteristic Burkitt cells are seen in the bone marrow and the peripheral blood.  This is an aggressive leukemia.


SODIUM FERULATE

An organic sodium salt resulting from the replacement of the proton from the 3-hydroxy group of ferulic acid by a sodium ion.


ureidoacrylic acid

The (Z)-3-ureido derivative of acrylic acid.


Nasal Cavity Neuroendocrine Neoplasm

description: A neuroendocrine neoplasm that arises from the nasal cavity.


Nasal Cavity Neuroendocrine Carcinoma

description: A neuroendocrine carcinoma that arises from the nasal cavity.


name: Nasal Cavity Large Cell Neuroendocrine Carcinoma

description: A large cell neuroendocrine carcinoma that arises from the nasal cavity.


name: Nasal Cavity Small Cell Neuroendocrine Carcinoma

description: A small cell neuroendocrine carcinoma that arises from the nasal cavity.


peri-centrosomal recycling endosome

category: biolink:CellularComponent biolink:AnatomicalEntity biolink:PhysicalEssence biolink:OrganismalEntity biolink:SubjectOfInvestigation biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing biolink:PhysicalEssenceOrOccurrent

description: A recycling endosome that is organized around the microtubule organizing center, close to the nucleus. This is the main recycling endosome of most cells. It receives input from the Golgi as well as recycled molecules from early endosomes.


A member of the class of  methylpyridines that is pyridine carrying methyl substituents at positions 2 and 6.


name: Penile Undifferentiated Pleomorphic Sarcoma

description: A rare undifferentiated pleomorphic sarcoma that occurs in the penis.


An L-tryptophan derivative that is the 7-(3,3-dimethylallyl) derivative of L-tryptophan.


Non-Neoplastic Vision Disorder

description: A non-neoplastic disorder that causes a disturbance in normal vision. Representative examples include amblyopia, astigmatism, myopia, and cataracts.


Color Blindness, Inherited

description: Genetic based difficulty in distinguishing colors.


Optical Illusion

description: The visual perception of an image that differs from the reality of the image.


CDP-alpha-D-abequose

A CDP-D-abequose in which the anomeric centre of the pyranose fragment has alpha-configuration.


trifluoro-L-methionine

An L-alpha-amino acid, methionine, with the S-methyl group trifluoro-substituted.


victoria blue R

An iminium salt composed of 4-{[4-(dimethylamino)phenyl][4-(ethylamino)naphthalen-1-yl]methylidene}-N,N-dimethylcyclohexa-2,5-dien-1-iminium and chloride ions in a 1:1 ratio.


A member of the class of pretetramides that is 6-methyltetracene-2-carboxamide carrying six hydroxy substituents at positions 1, 3, 4, 10, 11 and 12.


A member of the class of pretetramides in which the only additional substituent is a methyl group at position 6.


name: Advanced Extracranial Malignant Solid Neoplasm

description: A malignant solid neoplasm that arises from any anatomic site other than the brain and has spread extensively to other anatomic sites or is no longer responding to treatment.


(6Z,9Z)-octadecadienoic acid

An octadecadienoic acid in which the two double bonds have Z-geochemistry and are located at positions 6 and 9.


An amino monosaccharide obtained by replacement of the 8-hydroxy group of 3-deoxy-alpha-D-manno-oct-2-ulopyranosonic acid by an amino group.


AMASTATIN

A tetrapeptide comprising (2S,3R)-3-amino-2-hydroxy-5-methylhexanoyl, L-valyl, L-valyl and L-aspartic acid units joined in sequence


DIMEDAZOL

A dimethylbenzimidazole carrying methyl substituents at positions 5 and 6.


A beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-N-acylsphingosine in which the acyl group specified is hexadecanoyl.


dexfenfluramine

The S-enantiomer of fenfluramine. It stimulates the release of serotonin and selectively inhibits its reuptake, but unlike fenfluramine it does not possess catecholamine agonist activity. It was formerly given by mouth as the hydrochloride in the treatment of obesity, but, like fenfluramine, was withdrawn wolrdwide following reports of valvular heart defects.


Ciliary Body Adenocarcinoma

description: An adenocarcinoma arising from the pigmented or non-pigmented ciliary epithelium.


Stage IIB Uveal Melanoma AJCC v7

description: Stage IIB includes: (T2b, N0, M0); (T3a, N0, M0).  T2b: Ciliary body and choroid: Tumor size category 2 with ciliary body involvement.  T3a: Iris: Tumor confluent with or extending into the ciliary body, choroid, or both, with sclera extension and secondary glaucoma. Ciliary body and choroid: Tumor size category 3 without ciliary body involvement and extraocular extension. N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage IIA Uveal Melanoma AJCC v7

description: Stage IIA includes: (T1b-d, N0, M0); (T2a, N0, M0). T1b: Iris: Tumor limited to the iris more than 3 clock hours in size.  Ciliary body and choroid: Tumor size category 1 with ciliary body involvement.  T1c: Iris: Tumor limited to the iris with secondary glaucoma.  Ciliary body and choroid: Tumor size category 1 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in diameter.  T1d: Ciliary body and choroid: Tumor size category 1 with ciliary body involvement and extraocular extension less than or equal to 5 mm in diameter. T2a: Iris: Tumor confluent with or extending into the ciliary body, choroid, or both, with secondary glaucoma.  Ciliary body and choroid: Tumor size category 2 without ciliary body involvement and extraocular extension. N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)


Metastatic Choroid Melanoma

description: Choroid melanoma that has spread from its primary site to another anatomic site.


name: Metastatic Malignant Neoplasm in the Uvea

description: A malignant neoplasm that has spread to the uvea from another anatomic site.


Uveal Melanocytoma

description: A subtype of ciliary body, iris, and choroidal nevi. It is intensely pigmented and composed of large, plump, polyhedral cells.


Choroid Spindle Cell Type A Melanoma

description: A choroid melanoma characterized by the presence of malignant spindle-shaped melanocytes with slender nuclei and no visible nucleoli.


name: Uveal Melanoma by Gene Expression Profile


name: Locally Advanced Unresectable Uveal Melanoma

description: Uveal melanoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.


Uveal Spindle Cell Type A Melanoma

description: A uveal melanoma characterized by the presence of malignant spindle-shaped melanocytes with slender nuclei and no visible nucleoli.


Stage III Uveal Melanoma AJCC v7

description: Stage III includes: IIIA (T2c-d, N0, M0); (T3b-c, N0, M0); (T4a, N0, M0); IIIB (T3d, N0, M0); (T4b-c, N0, M0); IIIC (T4d-e, N0, M0).  T2c: Ciliary body and choroid: Tumor size category 2 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in diameter. T2d: Ciliary body and choroid: Tumor size category 2 with ciliary body involvement and extraocular extension less than or equal to 5 mm in diameter. T3b: Ciliary body and choroid: Tumor size category 3 with ciliary body involvement. T3c: Ciliary body and choroid: Tumor size category 3 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in diameter. T4a: Iris: Tumor with extrascleral extension less than or equal to 5 mm in diameter.  Ciliary body and choroid: Tumor size category 4 without ciliary body involvement and extraocular extension.  T3d: Ciliary body and choroid: Tumor size category 3 with ciliary body involvement and extraocular extension less than or equal to 5 mm in diameter.  T4b: Iris: Tumor with extrascleral extension more than 5 mm in diameter.  Ciliary body and choroid: Tumor size category 4 with ciliary body involvement.  T4c: Ciliary body and choroid: Tumor size category 4 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in diameter.  T4d: Ciliary body and choroid: Tumor size category 4 with ciliary body involvement and extraocular extension less than or equal to 5 mm in diameter.  T4e: Ciliary body and choroid: Any tumor size category with extraocular extension more than 5 mm in diameter.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)


Uveal Class 2 Melanoma

description: Gene expression profiling that classifies uveal melanomas into a high-grade group.


Uveal Class 1a Melanoma

description: Uveal melanoma with low metastatic risk as defined by gene expression profiling.


Ciliary Body Nevus

description: A benign nevus that arises from the ciliary body. Only a small percentage of cases progress to ciliary body melanoma.


Stage IIIC Uveal Melanoma AJCC v7

description: Stage IIIC includes: T4d-e, N0, M0.  T4d: Ciliary body and choroid: Tumor size category 4 with ciliary body involvement and extraocular extension less than or equal to 5 mm in diameter.  T4e: Ciliary body and choroid: Any tumor size category with extraocular extension more than 5 mm in diameter.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)


Refractory Uveal Melanoma

description: Uveal melanoma that is resistant to treatment.


Choroidal Ganglioneuroma

description: A rare ganglioneuroma that arises from the choroid.


Uveal Melanocytic Neoplasm

description: A melanocytic neoplasm that arises from the iris, ciliary body, and choroid. This category includes nevus and its subtype melanocytoma, and melanoma.


name: Choroidal and Ciliary Body Melanoma by AJCC v8 Stage

description: A term that refers to the staging of choroidal and ciliary body melanoma, following the rules of the TNM AJCC v8 classification system.


Unresectable Uveal Melanoma

description: Uveal melanoma that is not amenable to surgical resection.


name: Stage IIB Choroidal and Ciliary Body Melanoma AJCC v8

description: Stage IIB includes: (T2b, N0, M0); (T3a, N0, M0).  T2b: Tumor size category 2 with ciliary body involvement. T3a: Tumor size category 3 without ciliary body involvement and extraocular extension. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 8th ed.)


Choroid Spindle Cell Type B Melanoma

description: A choroid melanoma characterized by the presence of malignant spindle-shaped melanocytes with larger nuclei and distinct nucleoli.


name: Stage IIIB Choroidal and Ciliary Body Melanoma AJCC v8

description: Stage IIIB includes: (T3d, N0, M0); (T4b-c, N0, M0). T3d: Tumor size category 3 with ciliary body involvement and extraocular extension less than or equal to 5 mm in largest diameter.  T4b: Tumor size category 4 with ciliary body involvement. T4c: Tumor size category 4 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in largest diameter. N0: No regional lymph node metastasis. M0: No distant metastasis.  (AJCC 8th ed.)


Uveal Class 1b Melanoma

description: Uveal melanoma with intermediate metastatic risk as defined by gene expression profiling.


name: Ciliary Body Spindle Cell Type B Melanoma

description: A ciliary body melanoma characterized by the presence of malignant spindle-shaped melanocytes with larger nuclei and distinct nucleoli.


Stage II Uveal Melanoma AJCC v7

description: Stage II includes: IIA (T1b-d, N0, M0); (T2a, N0, M0); IIB (T2b, N0, M0); (T3a, N0, M0).  T1b: Iris: Tumor limited to the iris more than 3 clock hours in size.  Ciliary body and choroid: Tumor size category 1 with ciliary body involvement.  T1c: Iris: Tumor limited to the iris with secondary glaucoma.  Ciliary body and choroid: Tumor size category 1 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in diameter.  T1d: Ciliary body and choroid: Tumor size category 1 with ciliary body involvement and extraocular extension less than or equal to 5 mm in diameter. T2a: Iris: Tumor confluent with or extending into the ciliary body, choroid, or both, with secondary glaucoma.  Ciliary body and choroid: Tumor size category 2 without ciliary body involvement and extraocular extension. T2b: Ciliary body and choroid: Tumor size category 2 with ciliary body involvement.  T3a: Iris: Tumor confluent with or extending into the ciliary body, choroid, or both, with sclera extension and secondary glaucoma. Ciliary body and choroid: Tumor size category 3 without ciliary body involvement and extraocular extension. N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)


name: Stage III Choroidal and Ciliary Body Melanoma AJCC v8

description: Stage III includes: IIIA (T2c-d, N0, M0); (T3b-c, N0, M0); (T4a, N0, M0); IIIB (T3d, N0, M0); (T4b-c, N0, M0); IIIC: (T4d-e, N0, M0). T2c: Tumor size category 2 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in largest diameter. T2d: Tumor size category 2 with ciliary body involvement and extraocular extension less than or equal to 5 mm in largest diameter. T3b: Tumor size category 3 with ciliary body involvement. T3c: Tumor size category 3 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in largest diameter. T4a: Tumor size category 4 without ciliary body involvement and extraocular extension. T3d: Tumor size category 3 with ciliary body involvement and extraocular extension less than or equal to 5 mm in largest diameter.  T4b: Tumor size category 4 with ciliary body involvement. T4c: Tumor size category 4 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in largest diameter. T4d: Tumor size category 4 with ciliary body involvement and extraocular extension less than or equal to 5 mm in largest diameter. T4e: Any tumor size category with extraocular extension more than 5 mm in largest diameter. N0: No regional lymph node metastasis. M0: No distant metastasis.  (AJCC 8th ed.)


Stage I Uveal Melanoma AJCC v7

description: Stage I includes: T1a, N0, M0.  T1a: Iris: Tumor limited to the iris not more than 3 clock hours in size.  Ciliary body and choroid: Tumor size category 1 without ciliary body involvement and extraocular extension.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)


name: Stage IIA Choroidal and Ciliary Body Melanoma AJCC v8

description: Stage IIA includes: (T1b-d, N0, M0); (T2a, N0, M0).  T1b: Tumor size category 1 with ciliary body involvement.  T1c: Tumor size category 1 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in largest diameter.  T1d: Tumor size category 1 with ciliary body involvement and extraocular extension less than or equal to 5 mm in largest diameter. T2a: Tumor size category 2 without ciliary body involvement and extraocular extension. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 8th ed.)


name: Stage I Choroidal and Ciliary Body Melanoma AJCC v8

description: Stage I includes: T1a, N0, M0. T1a: Tumor size category 1 without ciliary body involvement and extraocular extension.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 8th ed.)


name: Stage IV Choroidal and Ciliary Body Melanoma AJCC v8

description: Stage IV includes: (Any T, N1, M0); (Any T, Any N, M1a-c). N1: Regional lymph node metastasis or discrete tumor deposits in the orbit. M0: No distant metastasis. M1a: Distant metastasis, with the largest diameter of the largest metastasis measuring 3 cm or less. M1b: Distant metastasis, with the largest diameter of the largest metastasis measuring 3.1-8.0 cm. M1c: Distant metastasis, with the largest diameter of the largest metastasis measuring 8.1 cm or more.  (AJCC 8th ed.)


name: Ciliary Body Spindle Cell Type A Melanoma

description: A ciliary body melanoma characterized by the presence of malignant spindle-shaped melanocytes with slender nuclei and no visible nucleoli.


Stage IIIB Uveal Melanoma AJCC v7

description: Stage IIIB includes: (T3d, N0, M0); (T4b-c, N0, M0).  T3d: Ciliary body and choroid: Tumor size category 3 with ciliary body involvement and extraocular extension less than or equal to 5 mm in diameter.  T4b: Iris: Tumor with extrascleral extension more than 5 mm in diameter.  Ciliary body and choroid: Tumor size category 4 with ciliary body involvement.  T4c: Ciliary body and choroid: Tumor size category 4 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in diameter.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)


Metastatic Uveal Melanoma

description: Uveal melanoma that has spread from its primary site to another anatomic site.


Iris Mixed Cell Melanoma

description: A melanoma arising from the iris. It is characterized by the presence of a mixture of spindle A melanoma cells, spindle B melanoma cells, and epithelioid melanoma cells.


Stage IV Uveal Melanoma AJCC v7

description: Stage IV includes: (Any T, N1, M0); (Any T, Any N, M1a-c).  N1: Regional lymph node metastasis. M1a: Distant metastasis, with the largest diameter of the largest metastasis measuring 3 cm or less.  M1b: Distant metastasis, with the largest diameter of the largest metastasis measuring 3.1-8.0 cm.  M1c: Distant metastasis, with the largest diameter of the largest metastasis measuring 8.0 cm or more.  (AJCC 7th ed.)


Benign neoplasm of uveal tract

description: A neoplasm that arises from the uvea and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential..


name: Stage IIIC Choroidal and Ciliary Body Melanoma AJCC v8

description: Stage IIIC includes: T4d-e, N0, M0. T4d: Tumor size category 4 with ciliary body involvement and extraocular extension less than or equal to 5 mm in largest diameter. T4e: Any tumor size category with extraocular extension more than 5 mm in largest diameter. N0: No regional lymph node metastasis. M0: No distant metastasis.  (AJCC 8th ed.)


name: Metastatic Malignant Neoplasm in the Iris

description: A malignant neoplasm that has spread to the iris from another anatomic site.


name: Stage II Choroidal and Ciliary Body Melanoma AJCC v8

description: Stage II includes: IIA (T1b-d, N0, M0); (T2a, N0, M0); IIB (T2b, N0, M0); (T3a, N0, M0).  T1b: Tumor size category 1 with ciliary body involvement.  T1c: Tumor size category 1 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in largest diameter.  T1d: Tumor size category 1 with ciliary body involvement and extraocular extension less than or equal to 5 mm in largest diameter. T2a: Tumor size category 2 without ciliary body involvement and extraocular extension. T2b: Tumor size category 2 with ciliary body involvement. T3a: Tumor size category 3 without ciliary body involvement and extraocular extension. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 8th ed.)


Uveal Melanoma by AJCC v7 Stage

description: A term that refers to the staging of uveal melanoma, following the rules of the TNM AJCC v7 classification system.


Uveal Spindle Cell Type B Melanoma

description: A uveal melanoma characterized by the presence of malignant spindle-shaped melanocytes with larger nuclei and distinct nucleoli.


Uveal Class 1 Melanoma

description: Gene expression profiling that classifies uveal melanomas into a low-grade group.


Uveal Nevus

description: A benign nevus derived from melanocytes of the uveal tract. Only a small percentage of cases progress to uveal melanoma.


Advanced Uveal Melanoma

description: Uveal melanoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Iridociliary Melanoma

description: Melanoma that affects both the iris and ciliary body.


Iris Epithelioid Cell Melanoma

description: An iris melanoma characterized by the presence of malignant large epithelioid melanocytes.


name: Metastatic malignant neoplasm to ciliary body

description: A malignant neoplasm that has spread to the ciliary body from another anatomic site.


myristoleamide

A primary fatty amide resulting from the formal condensation of the carboxy group of myristoleic acid with ammonia.


Conjunctival keratoacanthomas

description: A rapidly growing neoplasm that arises from the conjunctiva. It is characterized by a proliferation of squamous cells, acanthosis, keratinization, dysplasia, increased mitotic activity, and a central crater filled with keratinocytes. It is considered a variant of well-differentiated squamous cell carcinoma with distinct clinical behavior.


Conjunctival Spindle Cell Carcinoma

description: A variant of conjunctival squamous cell carcinoma characterized by the presence of malignant spindle cells and/or pleomorphic cells.


A branched heptasaccharide derivative comprising one mannopyranose and six D-arabinofuranose units, in an assembly consisting of two arabinose residues linked alpha(1->5), with beta-arabinosyl-(1->2)-alpha-arabinosyl and alpha-mannosyl-(1->5)-beta-arabinosyl-(1->2)-alpha-arabinosyl units linked to respectively the 3- and 5-positions of the arabinose residue distal from the reducing-end residue.


Stage II Fallopian Tube Cancer AJCC v8

description: Stage II includes: T2, N0, M0. T2: Fallopian tube cancer with tumor involving fallopian tubes with pelvic extension below pelvic brim. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)


Stage IIA Fallopian Tube Cancer AJCC v8

description: Stage IIA includes: T2a, N0, M0. T2a: Fallopian tube cancer with extension and/or implants on the uterus and/or fallopian tube(s) and/or ovaries. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)


Stage IIB Fallopian Tube Cancer AJCC v8

description: Stage IIB includes: T2b, N0, M0. T2b: Fallopian tube cancer with tumor extension to and/or implants on other pelvic tissues. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)


N,N',N'',N'''-tetraacetylchitotetraose

An amino tetrasaccharide consisting of three 2-acetamido-2-deoxy-beta-D-glucopyranose residues and a 2-acetamido-2-deoxy-D-glucopyranose residue joined in sequence by (1->4) glycosidic bonds.


(S)-nandinine

A berberine alkaloid that is 5,8,13,13a-tetrahydro-2H,6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinoline carrying hydroxy and methoxy substituents at positions 9 and 10 respectively.


CANADINE

The (S)-enantiomer of canadine.


SCOULERINE

A berberine alkaloid isolated from  Corydalis saxicola.


(S)-tetrahydrocolumbamine

A berberine alkaloid consisting of columbamine having four extra hydrogens at positions 5, 8, 13 and 13a and (S)-configuration.


(R)-canadine

A canadine which has R configuration.


TETRAHYDROBERBERINE

A berberine alkaloid that is 5,8,13,13a-tetrahydro-6H-[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinoline substituted by methoxy groups at positions 9 and 10.


STEPHARANINE

A berberine alkaloid with formula C19H18NO4 that is isolated from several species of Stephania.


A berberine alkaloid that is  berbine substituted by hydroxy groups at positions 2, 3, 9 and 10.


STYLOPINE

A berberine alkaloid isolated from the plants of the family papaveraceae.


Laryngeal Paraganglioma

description: An extra-adrenal parasympathetic paraganglioma arising from paraganglia adjacent to the larynx.  Patients may present with hoarseness and dysphagia.


A nucleobase analogue that is uracil substituted with a (2-hydroxyethyl)amino group at position 6 and an (E)-(2-oxopropylidene)amino group at position 5; one of 20 modifications to the potent microbial riboflavin-based metabolite antigen 5-(2-oxopropylideneamino)-6-D-ribityl aminouracil (5-OP-RU), an activator of mucosal-associated invariant T (MAIT) cells when presented by the MR1 protein (reported in MED:32123373).


A branched amino oligosaccharide that is a docosasaccharide derivative consisting of a linear trisaccharide of beta-D-mannose and two N-acetyl-beta-D-glucosamine residues all linked in sequence (1->4), to the mannosyl residue of which are linked two beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl linear nonasaccharide units [linked (1->3) and (1->6)], while to the N-acetyl-beta-D-glucosamine residue at the reducing end is linked (1->6) an alpha-L-fucose residue.


Finding by Site or System

category: biolink:PhenotypicFeature biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

description: A term that refers to the classification of a clinical or laboratory finding according to the anatomic site or system that is involved.


name: Postpartum Mental or Behavioral Disorder

description: A maternal mental or behavioral disorder that occurs in the period following the birth of a child and extending up to six weeks after delivery.


Jacksonian Seizure

description: A partial motor seizure that begins in a single area of the body and progresses to include other areas on the same side of the body.


Rheumatic tricuspid valve stenosis

description: Tricuspid valve stenosis secondary to rheumatic fever.


Non-Febrile Seizure

description: A seizure that is not associated with fever.


Rheumatic mitral stenosis

description: Mitral valve stenosis secondary to rheumatic fever.


Congenital stenosis of pulmonary valve

description: Pulmonary valve stenosis that is present at birth.


Migraine-triggered seizure

description: A seizure triggered by a migraine.


Subclinical Seizure

description: A seizure with no apparent symptoms.


Seizure Related to COVID-19

description: Seizure in a patient with probable or confirmed acute COVID-19.


Nervous System Finding

description: Symptoms, physical examination results, and/or laboratory test results related to the nervous system.


Grade 3 Seizure, ASTCT ICANS

description: Any clinical seizure focal or generalized that resolves rapidly or nonconvulsive seizures on EEG that resolve with intervention, as defined by the American Society for Transplantation and Cellular Therapy (ASTCT) and the Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) Consensus Grading for Adults.


Digestive System Finding

description: Symptoms, physical examination results, and/or laboratory test results related to the digestive system.


Neurological Signs and Symptoms

description: A term that refers to the clinical manifestations resulting from pathologic processes that affect the central and peripheral nervous system.


Integumentary System Finding

description: Symptoms, physical examination results, and/or laboratory test results related to the integumentary system.


Grade 4 Seizure, ASTCT ICANS

description: Life-threatening prolonged seizure (>5 min); or repetitive clinical or electrical seizures without return to baseline in between seizures, as defined by the American Society for Transplantation and Cellular Therapy (ASTCT) and the Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) Consensus Grading for Adults.


Cardiovascular System Finding

description: Symptoms, physical examination results, and/or laboratory test results related to the cardiovascular system.


Syncope Related to COVID-19

description: Syncope in a patient with probable or confirmed acute COVID-19.


Refractory Erectile Dysfunction

description: Erectile dysfunction that does not respond to treatment.


name: Locally Advanced Malignant Peripheral Nerve Sheath Tumor

description: A malignant peripheral nerve sheath tumor that has spread from its original site of growth to nearby tissues or lymph nodes.


Vulvar Acquired Melanocytic Nevus

description: A benign nevus that arises from the vulva during childhood and grows with increasing age.


maleimide

A cyclic dicarboximide in which the two carboacyl groups on nitrogen together with the nitogen itself form a 1H-pyrrole-2,5-dione structure.


COCARBOXYLASE

An organic chloride salt of thiamine(1+) diphosphate.


A trifluoroacetamide resulting from the formal condensation of the amino group of 8-aminooctan-1-ol with trifluoroacetic acid.


The stable isotope of vanadium with relative atomic mass 50.943964, 99.8 atom percent natural abundance and nuclear spin 7/2.


A diarylheptanoid that is (6E)-6-hepten-3-ol substituted by a 3,4-dihydroxyphenyl group at position 1 and a 4-hydroxyphenyl group at position 7 (the 3R-stereoisomer). It has been isolated from the rhizomes of Curcuma kwangsiensis.


ETHIRIMOL

An aminopyrimidine that is 2-ethylaminopyrimidin-4-one carrying butyl and methyl substituents at positions 5 and 6 respectively. A fungicide first marketed in 1970 and used as a seed treatment for diseaases such as damping-off, it is not licensed for use within the European Union.


pyrimidine fungicide

Any pyrimidine antifungal agent that has been used as a fungicide.


anilinopyrimidine fungicide

Any pyrimidine fungicide in which the pyrimidine ring is substituted by the nitrogen of an aniline moiety.


MEPANIPYRIM

A member of the class of aminopyrimidines that is N-phenylpyrimidin-2-amine carrying additional methyl and 1-propynyl substituents at positions 4 and 6 respectively. A fungicide used to control a wide range of diseases including grey mould on strawberries, tomatoes and cucumabers, and scab on apples and pears.


diflumetorim

A racemate comprising equimolar amounts of (R)- and (S)-diflumetorim.  Used mainly to control powdery mildew and rust on ornamental crops.


CYPRODINIL

A member of the class of aminopyrimidine that is N-phenylpyrimidin-2-amine carrying additional cyclopropyl and methyl substituents at positions 4 and 6 respectively. A broad spectrum fungicide used to control a range of pathogens including Tapesia yallundae, Botrytis spp., Alternaria spp. and Rhynchospium secalis. Whilst it is a recognised irritant no serious human health concerns have been identified. It is moderately toxic to birds as well as most aquatic organisms and earthworms, but it is not considered toxic to honeybees.


FENARIMOL

A racemate comprising equimolar amounts of (R)- and (S)-fenarimol. A sterol demethylation inhibitor, it is used as a fungicide for the treatment of blackspot, mildew and rust in tomatoes, peppers and melons, but is not approved for use within the European Union.


NUARIMOL

A racemate comprising equimolar amounts of (R)- and (S)-nuarimol. A sterol demethylation inhibitor, it is used as a systemic fungicide but is not approved for use within the European Union.


PYRIMETHANIL

A member of the class of aminopyrimidines that is N-phenylpyrimidin-2-amine carrying two additional methyl substituents at positions 4 and 6.  A fungicide used to control grey mould on fruit, vegetables and ornamentals as well as leaf scab on pome fruit. Also commonly employed to control Botrytis cinerea throughout the winemaking process in grapes, must, fermenting must and wine.


FERIMZONE

A member of the class of pyrimidines that is 2-hydrazino-4,6-dimethylpyrimidine in which the two amino hydrogens are replaced by a 1-(2-methylphenyl)ethylidene group. It is used for the control of fungal diseases in rice.


DIMETHIRIMOL

A member of the class of aminopyrimidines that is 2-dimethylaminopyrimidine carrying methyl, butyl and hydroxy substituents at posiitons 4, 5 and 6 respectively. A fungicide first marketed in 1970, and used particularly in glasshouses to control powdery mildew, it is no longer approved for use within the European Union.


BUPIRIMATE

A member of the class of aminopyrimidines that is 2-ethylaminopyrimidine carrying methyl, butyl and dimethylaminosulfooxy substituents at posiitons 4, 5 and 6 respectively.


Mucous polyp of cervix

description: A polypoid lesion that arises from the cervix and contains mucus.


17-octadecynoic acid

An acetylenic fatty acid that is octadecanoi acid (stearic acid) which has been doubly dehydrogenated at positions 17 and 18 to give the corresponding alkynoic acid.


WHO Grade 1 Glioma

description: A category of low grade gliomas that includes subependymal giant cell astrocytoma, pilocytic astrocytoma, angiocentric glioma, and subependymoma.


Adult Myxopapillary Ependymoma

description: A myxopapillary ependymoma that occurs during adulthood.


Adult Pilocytic Astrocytoma

description: A pilocytic astrocytoma occurring in adults.


Recurrent WHO Grade 1 Glioma

description: The reemergence of WHO grade 1 glioma after a period of remission.


Adult Subependymoma

description: A subependymoma that occurs during adulthood.


Refractory WHO Grade 1 Glioma

description: WHO grade 1 glioma that is resistant to treatment.


name: Adult Subependymal Giant Cell Astrocytoma

description: A subependymal giant cell astrocytoma occurring in adults.


Childhood Myxopapillary Ependymoma

description: A myxopapillary ependymoma that occurs during childhood.


name: Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8

description: Stage II includes: T2, N0, M0. T2: Tumor 2 cm or larger, but smaller than 4 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


name: 1,2-Cyclohexanedicarboxylic acid, 2-methylpent-3-yl nonyl ester


azanylylidene group

A group used for compounds where a trivalent N atom replaces the group CH.


Parotid Gland Warthin Tumor

description: An adenoma that arises from the parotid gland. It is characterized by an oncocytic, often papillary, epithelial component, dense lymphoid stroma, and cystic spaces. A strong association with smoking has been reported. It typically presents as a painless swelling in the lower portion of the parotid gland.


An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of oscr#19.


An alpha-D-glucosyl-(1->4)-D-mannopyranose in which the anomeric hydroxy group has alpha configuration.


Skin Cavernous Hemangioma

description: A cavernous hemangioma arising from the skin.


17-epiestriol 16-O-(beta-D-glucuronide)

A steroid glucosiduronic acid that is 17-epiestriol having a single beta-D-glucuronic acid residue attached at position 16.


ANTHRARUFIN

A  dihydroxyanthraquinone that is anthracene-9,10-dione substituted by hydroxy groups at positions 1 and 5.


Penile Lymphoepithelioma-Like Carcinoma

description: A variant of penile squamous cell carcinoma characterized by the presence of islands of malignant cells with uniform vesicular nuclei and prominent nucleoli, and a dense lymphocytic infiltrate.


Penile Carcinoma Cuniculatum

description: A variant of verrucous carcinoma of the penis. It is characterized by a labyrinthine growth pattern.


Penile Lymphoma

description: A lymphoma that arises from penile skin, subcutis, corpora cavernosa, and spongiosum. Diffuse large B-cell lymphoma is the most common primary penile lymphoma. (WHO 2016)


Stage 0is Penile Cancer AJCC v8

description: Stage 0is includes: Tis, N0, M0. Tis: Penile cancer with a finding of carcinoma in situ (penile intraepithelial neoplasia [PeIN]). N0: No lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Refractory Penile Carcinoma

description: Penile carcinoma that is resistant to treatment.


Penile Lymphangioma

description: A lymphangioma that occurs in the skin of the penis.


Childhood Malignant Penile Neoplasm

description: A rare malignant neoplasm of the penis that occurs during childhood.


Stage IIA Penile Cancer AJCC v8

description: Stage IIA includes: (T1b, N0, M0); (T2, N0, M0). T1b: Penile cancer with tumor exhibiting lymphovascular invasion and/or perineural invasion or is high grade (i.e., grade 3 or sarcomatoid). T2: Penile cancer with tumor invading into corpus spongiosum (either glans or ventral shaft) with or without urethral invasion. N0: No lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage III Penile Cancer AJCC v8

description: Stage III includes: IIIA: T1-3, N1, M0; IIIB: T1-3, N2, M0. T1: Glans: Penile cancer with tumor invading lamina propria. Foreskin: Penile cancer with tumor invading dermis, lamina propria, or dartos fascia. Shaft: Penile cancer with tumor invading connective tissue between epidermis and corpora regardless of location. All sites with or without lymphovascular invasion or perineural invasion and is or is not high grade. T2: Penile cancer with tumor invading into corpus spongiosum (either glans or ventral shaft) with or without urethral invasion. T3: Penile cancer with tumor invading into corpora cavernosum (including tunica albuginea) with or without urethral invasion. N1: Penile cancer with two or less unilateral inguinal metastases, no extranodal extension. N2: Penile cancer with three or more unilateral inguinal metastases or bilateral metastases. M0: No distant metastasis. (AJCC 8th ed.)


Penile Hemangioma

description: A hemangioma that occurs in the skin of the penis.


name: Grade II Penile Intraepithelial Neoplasia

description: Penile intraepithelial neoplasia characterized by the proliferation of transformed basaloid cells that occupy the lower two thirds of the epithelial thickness.


Penis carcinoma recurrent

description: A carcinoma of the penis that reappears after a period of remission.


Unresectable Penile Carcinoma

description: Penile carcinoma that is not amenable to surgical resection.


Penile Mucosal Melanoma

description: A melanoma that arises from the mucosa of the penis.


name: Penile Human Papillomavirus-Independent Squamous Cell Carcinoma

description: A squamous cell carcinoma that arises from the penis and is not caused by human papillomavirus infection. Morphologic variants include pseudohyperplastic, pseudoglandular, verrucous, papillary, and sarcomatoid carcinoma.


Penile intraepithelial neoplasia

description: A precancerous neoplastic lesion that arises from the penis. It is characterized by dysplastic changes of the squamous epithelium with an intact basement membrane.


Bowenoid papulosis of penis

description: A cutaneous, usually multifocal lesion in the penis characterized by the presence of verrucous papules.  It is caused by human papillomavirus infection.  Morphologically there is bowenoid dysplasia present.  Progression to invasive carcinoma is infrequent.


Penile Schwannoma

description: A schwannoma that occurs in the penis.


Myointimoma

description: A rare benign mesenchymal neoplasm that occurs in the glans and corpora of the penis. It is characterized by the proliferation of spindle-shaped myofibroblasts in the intravascular spaces.


Penile Neurofibroma

description: A neurofibroma that occurs in the penis.


name: Basaloid (Undifferentiated) Penile Intraepithelial Neoplasia

description: Intraepithelial neoplasia of the penis characterized by full-thickness replacement of the squamous epithelium by immature, small, monotonous, basophilic cells. The cells have round to oval nuclei, inconspicuous nucleoli, and scant cytoplasm. Apoptosis and mitotic figures are prominent. (WHO 2016)


Stage IV Penile Cancer AJCC v8

description: Stage IV includes: (T4, Any N, M0); (Any T, N3, M0); (Any T, Any N, M1). T4: Penile cancer with tumor invading into adjacent structures (i.e., scrotum, prostate, pubic bone). N3: Penile cancer with extranodal extension of lymph node metastases or pelvic lymph node metastases. M1: Distant metastasis present. (AJCC 8th ed.)


name: Penile Clear Cell Squamous Cell Carcinoma

description: A variant of penile squamous cell carcinoma characterized by the presence of malignant cells with clear cytoplasm.


name: Penile Squamous Cell Carcinoma, Not Otherwise Specified

description: A penile squamous cell carcinoma characterized by the absence of special morphologic features and lack of information on p16 immunohistochemistry and human papilloma virus testing status.


name: Warty (Bowenoid) Penile Intraepithelial Neoplasia

description: Intraepithelial neoplasia of the penis characterized by a slightly spiking papillomatous surface with atypical parakeratosis. There is prominent cellular pleomorphism, koilocytosis, and mitoses. Unlike in basaloid penile intraepithelial neoplasia, there is squamous maturation. (WHO 2016)


Stage IIIA Penile Cancer AJCC v8

description: Stage IIIA includes: T1-3, N1, M0. T1: Glans: Penile cancer with tumor invading lamina propria. Foreskin: Penile cancer with tumor invading dermis, lamina propria, or dartos fascia. Shaft: Penile cancer with tumor invading connective tissue between epidermis and corpora regardless of location. All sites with or without lymphovascular invasion or perineural invasion and is or is not high grade. T2: Penile cancer with tumor invading into corpus spongiosum (either glans or ventral shaft) with or without urethral invasion. T3: Penile cancer with tumor invading into corpora cavernosum (including tunica albuginea) with or without urethral invasion. N1: Penile cancer with two or less unilateral inguinal metastases, no extranodal extension. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIB Penile Cancer AJCC v8

description: Stage IIB includes: T3, N0, M0. T3: Penile cancer with tumor invading into corpora cavernosum (including tunica albuginea) with or without urethral invasion. N0: No lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Penile Condyloma Acuminatum

description: A human papillomavirus-related benign neoplasm affecting the penis. Most often it arises from the glans penis in young men. It usually presents with a nodular wart. Morphologically, it is characterized by an exophytic papillary proliferation of squamous cells and acanthosis. Most cases either resolve spontaneously or do not recur following removal.


Penile Adenosquamous Carcinoma

description: An extremely rare carcinoma that arises from the penis and is characterized by the presence of glandular and squamous components.


Penile Cancer by AJCC v8 Stage

description: A term that refers to the staging of penile cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to penile squamous cell carcinoma and associated histologic subtypes. It does not apply to urethral carcinomas, sarcomas, and melanomas. (from AJCC 8th Ed.)


name: Unresectable Penile Squamous Cell Carcinoma

description: Penile squamous cell carcinoma that is not amenable to surgical resection.


Penile Cutaneous Melanoma

description: A melanoma that arises from the skin of the penis.


name: Differentiated penile intraepithelial neoplasia

description: Intraepithelial neoplasia of the penis that is not caused by human papillomavirus infection. It usually presents as a solitary white or pink macule or plaque that may be slightly elevated. A background of long-standing lichen sclerosus is often present. It is characterized by a thickened epithelium, subtle abnormal cellular maturation, and atypical basal layer cells. Parakeratosis is common. (WHO 2016)


Penile Pseudohyperplastic Carcinoma

description: A multifocal, extremely differentiated squamous cell carcinoma of the penis. It typically occurs in older patients and is associated with lichen sclerosus.


Adult Penile Carcinoma

description: A carcinoma of the penis that occurs during adulthood.


Penile Epithelioid Hemangioendothelioma

description: An epithelioid hemangioendothelioma that occurs in the penis.


Penile Leiomyoma

description: A leiomyoma that occurs in the penis.


Penile Soft Tissue Neoplasm

description: A rare mesenchymal neoplasm that arises from the penis.


Penile Pseudoglandular Carcinoma

description: A penile squamous cell carcinoma characterized by the formation of gland-like structures.


Stage 0 Penile Cancer AJCC v8

description: Stage 0 includes: 0is: Tis, N0, M0; 0a: Ta, N0, M0. Tis: Penile cancer with a finding of carcinoma in situ (penile intraepithelial neoplasia [PeIN]). Ta: Penile cancer with a finding of noninvasive localized squamous cell carcinoma. N0: No lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIIB Penile Cancer AJCC v8

description: Stage IIIB includes: T1-3, N2, M0. T1: Glans: Penile cancer with tumor invading lamina propria. Foreskin: Penile cancer with tumor invading dermis, lamina propria, or dartos fascia. Shaft: Penile cancer with tumor invading connective tissue between epidermis and corpora regardless of location. All sites with or without lymphovascular invasion or perineural invasion and is or is not high grade. T2: Penile cancer with tumor invading into corpus spongiosum (either glans or ventral shaft) with or without urethral invasion. T3: Penile cancer with tumor invading into corpora cavernosum (including tunica albuginea) with or without urethral invasion. N2: Penile cancer with three or more unilateral inguinal metastases or bilateral metastases. M0: No distant metastasis. (AJCC 8th ed.)


name: Human Papillomavirus-Related Penile Intraepithelial Neoplasia

description: Intraepithelial neoplasia of the penis caused by human papillomavirus infection.


name: Penile Malignant Peripheral Nerve Sheath Tumor

description: A rare malignant peripheral nerve sheath tumor that occurs in the penis.


Penile Papillary-Basaloid Carcinoma

description: A variant of penile basaloid squamous cell carcinoma. It is characterized by a papillary exophytic or endophytic growth pattern.


Stage 0a Penile Cancer AJCC v8

description: Stage 0a includes: Ta, N0, M0. Ta: Penile cancer with a finding of noninvasive localized squamous cell carcinoma. N0: No lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


name: Low Grade Penile Intraepithelial Neoplasia

description: Penile intraepithelial neoplasia characterized by the proliferation of transformed basaloid cells that occupy the lower one third of the epithelial thickness.


Penile Epithelioid Hemangioma

description: An epithelioid hemangioma that occurs in the skin of the penis.


name: High Grade Penile Intraepithelial Neoplasia

description: Penile intraepithelial neoplasia characterized by the proliferation of transformed basaloid cells that occupy either the lower two thirds of the epithelial thickness (grade II) or the entire thickness of the epithelium (grade III, Bowen atypia, or squamous cell carcinoma in situ).


Stage II Penile Cancer AJCC v8

description: Stage II includes: IIA: (T1b, N0, M0); (T2, N0, M0); IIB: (T3, N0, M0). T1b: Penile cancer with tumor exhibiting lymphovascular invasion and/or perineural invasion or is high grade (i.e., grade 3 or sarcomatoid). T2: Penile cancer with tumor invading into corpus spongiosum (either glans or ventral shaft) with or without urethral invasion. T3: Penile cancer with tumor invading into corpora cavernosum (including tunica albuginea) with or without urethral invasion. N0: No lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Penile Warty-Basaloid Carcinoma

description: A squamous cell carcinoma that arises from the penis. It is characterized by warty (condylomatous) and basaloid features.


Penile Angiosarcoma

description: A rare angiosarcoma that affects the penis.


name: Warty-Basaloid Penile Intraepithelial Neoplasia

description: Intraepithelial neoplasia of the penis characterized by the presence of a variable mixture of warty and basaloid cells. (WHO 2016)


melanoma of penis

description: A melanoma that arises from the penis. It may be cutaneous or mucosal. The most common site of involvement is glans penis.


Metastatic Penile Cancer

description: Carcinoma of the penis that has spread from its original site of growth to another anatomic site.


Stage I Penile Cancer AJCC v8

description: Stage I includes: T1a, N0, M0. T1a: Penile cancer with tumor without lymphovascular invasion or perineural invasion and is not high grade (i.e., grade 3 or sarcomatoid). N0: No lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Penile Mucoepidermoid Carcinoma

description: An extremely rare carcinoma that arises from the penis and is characterized by the presence of mucinous and squamous components.


Penile Rhabdomyosarcoma

description: A rhabdomyosarcoma that occurs in the penis. It usually affects young children. Embryonal rhabdomyosarcoma is the most common type.


Locally Advanced Penile Carcinoma

description: Penile carcinoma that has spread to nearby tissues or lymph nodes.


nitrogen-13 atom

The radioactive isotope of nitrogen with relative atomic mass 13.0057386. The longest-lived nitrogen radionuclide with half-life of 9.965 min.


nitrogen-14 atom

The stable isotope of nitrogen with relative atomic mass 14.003074. The most abundant (99.63 atom percent) isotope of naturally occurring nitrogen.


nitrogen-15 atom

The stable isotope of nitrogen with relative atomic mass 15.000109. The least abundant (0.368 atom percent) isotope of naturally occurring nitrogen.


Current Hepatitis B Infection

description: Hepatitis B infection is evident at the time of testing.


N-hexacosenoylsphingosine

An N-acylsphingosine in which the acyl moiety contains 26 carbons and 1 double bond.


A branched hexasaccharide comprised of five alpha-D-mannose residues linked as shown and also to a 3-deoxy-alpha-D-manno-oct-2-ulosonic acid (3-deoxy-D-manno-oct-2-ulosonic acid; Kdo) residue at the reducing end, corresponding to the core oligosaccharide of the phytopathogenic bacterium Rhizobacterium radiobacter strain Rv3.


2-(acetamidomethylidene)succinic acid

A dicarboxylic acid that is succinic acid substituted by a acetamidomethylidene group at position 2.


Stage IIIB Anal Cancer AJCC v8

description: Stage IIIB includes: T4, N0, M0. T4: Tumor of any size invading adjacent organ(s), such as the vagina, urethra, or bladder. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


cis-10-pentadecenoic acid

The cis-isomer of pentadec-10-enoic acid.


Ala-Met-Asp-Tyr

A tetrapeptide composed of L-alanine, L-methionine, L-aspartic acid and L-tyrosine joined in sequence by peptide linkages.


A member of the class of imidazoles bearing methyl, amino and selenocarboxamido substituents at positions 1, 4 and 5 respectively.


rhamnosyl group

A glycosyl group obtained by removing the hydroxy group from the hemiacetal function of a rhamnose and, by extension, of a lower oligosaccharide having rhamnose at the reducing end.


Met-His

A dipeptide formed from L-methionine and L-histidine residues.


An Fe4S4 iron-sulfur cluster in which each sulfur is attached to three of the iron atoms.


Esophageal Fistula

description: An abnormal communication between the esophagus and another organ or anatomic site.


Ile-Gly

A dipeptide formed from L-isoleucine and glycine residues.


A glucotriose consisting of two beta-D-glucopyranose residues and a D-glucopyranose residue joined in sequence by (1->6) and (1->4) glycosidic bonds.


glucotriose

Any trisaccharide composed of 3 glucose moieties.


isomaltotriose

A glucotriose consisting of two alpha-D-glucopyranose residues and a D-glucopyranose residue joined in sequence by (1->6) glycosidic bonds.


A glucotriose consisting of two alpha-D-glucose residues and a beta-D-glucose at the reducing end in a linear sequence and joined by (1->6) linkages.


isobemisiose

A glucotriose that is alpha-D-glucopyranosyl-(1->6)-alpha-D-glucopyranoside in which the anomeric hydroxy group has been converted into the corresponding alpha-D-glucopyranoside. An unusual trisaccharide abundant in the silverleaf whitefly, Bemisia argentifolii.


A glucotriose consisting of two molecules of alpha-D-glucopyranose and a D-glucopyranose moiety joined together in sequence by (1->4) and (1->3) glycosidic bonds.


A glucotriose consisting of alpha-D-glucopyranose, beta-D-glucopyranose and D-glucopyranose residues joined in sequence by (1->6) glycosidic bonds.


A glucotriose consisting of three glucose units connected via alpha-(1->3) linkages. Also known as nigerotriose.


A glucotriose consisting of three D-glucose units joined by beta-(1->2)-linkages


A glucotriose consisting of three molecules of beta-D-glucopyranose joined in a linear sequence by 1->2 glycosidic linkages.


A glucotriose consisting of three molecules of beta-D-glucopyranose joined in a linear sequence by 1->6 glycosidic linkages.


A glucotriose consisting of beta-D-glucopyranose, alpha-D-glucopyranose and D-glucopyranose residues joined in sequence by (1->3) and (1->2) glycosidic bonds.


A glucotriose consisting of three alpha-D-glucopyranose residues joined in sequence by (1->6) and (1->4) glycosidic bonds.


A glucotriose consisting of a beta-D-glucopyranose residue and two alpha-D-glucopyranose residues joined in sequence by (1->4) and (1->1) glycosidic bonds.


A glucotriose that is D-glucopyranose in which the hydroxy groups at positions 2 and 6 have been converted into the corresponding D-glucopyranosyl derivatives.


A glucotriose consisting of alpha-D-glucopyranose, D-glucopyranose and beta-D-glucopyranose residues joined in sequence by (1->3) and (1->2) glycosidic bonds.


A glucotriose composed of three beta-D-glucose units joined by two (1->3)-linkages.


A glucotriose consisting of alpha-D-glucopyranose in which the hydroxy groups at 2 and 3 have each been converted into the corresponding beta-D-glucopyranosyl derivatives.


A glucotriose consisting of three molecules of alpha-D-glucopyranose joined in a linear sequence by 1->6 glycosidic linkages.


A glucotriose consisting of three molecules of beta-D-glucopyranose joined in a linear sequence by (1->4) and (1->6) glycosidic linkages.


A glucotriose that is D-glucopyranose in which the hydroxy groups at positions 3 and 6 have each been converted into the corresponding beta-D-glucopyranosyl derivative.


A glucotriose consisting of alpha-D-glucopyranose, beta-D-glucopyranose and D-glucopyranose attached in sequence by (1->2) and (1->6) glycosidic linkages.


A maltotriose trisaccharide in which the glucose residue at the reducing end is in the pyranose form.


A glucotriose that is alpha-D-glucopyranose in which the hydroxy groups at positions 2 and 4 have been converted to the corresponding alpha-D-glucopyranosyl and beta-D-glucopyranosyl derivatives, respectively.


A glucotriose that is D-glucopyranose in which the hydroxy groups at positions 2 and 6 have each been converted into their corresponding alpha-D-glucopyranosyl derivative.


A glucotriose consisting of two beta-D-glucopyranosyl residues and a D-glucopyranose residue joined in sequence by (1->2) and (1->4) glycosidic bonds.


A glucotriose consisting of one beta-D-glucose and two alpha-D-glucose residues linked sequentially (1->4) and (1->2).


A glucotriose that is D-glucopyranose in which the hydroxy groups at positions 4 and 6 have been converted into the corresponding beta-D-glucopyranoside and alpha-D-glucopyranoside, respectively.


A glucotriose consisting of two alpha-D-glucose residues and a beta-D-glucose at the reducing end joined in sequence  by (1->4) glycosidic linkages.


A glucotriose that is beta-D-glucopyranose in which the hydroxy groups at positions 4 and 6 have been converted into the corresponding alpha-D-glucopyranosyl and beta-D-glucopyranosyl derivatives, respectively.


A glucotriose consisting of three molecules of beta-D-glucopyranose attached in sequence by (1->6) and (1->3) glycosidic linkages.


A glucotriose that is beta-D-glucopyranose in which the hydroxy groups at positions 2 and 6 have been converted into D-glucopyranosyl derivatives.


A glucotriose consisting of D-glucopyranose, alpha-D-glucopyranose and beta-D-glucopyranose residues joined in sequence by two (1->4) glycosidic bonds. The configuration of the anomeric centre at the non-reducing terminus is not specified.


A glucotriose consisting of three beta-D-gluopyranose residues joined in sequence by (1->3) and (1->4) glycosidic bonds.


A glucotriose that is beta-D-glucopyranose in which the hydroxy groups at positions 2 and 3 have each been converted into the corresponding beta-D-glucopyranoside.


A glucotriose consisting of alpha-D-glucopyranose, beta-D-glucopyranose and D-glucopyranose residues joined in sequence by (1->2) glycosidic bonds.


A glucotriose that is beta-D-glucose in which the hydroxy groups at positions 2 and 4 have each been converted to the corresponding beta-D-glucoside.


A glucotriose consisting of three beta-D-glucopyranose residues joined in sequence by (1->3) and (1->6) glycosidic bonds.


A glucotriose consisting of one beta-D-glucopyranose and two alpha-D-glucopyranose residues joined in sequence by (1->2) and (1->3) glycosidic linkages.


A trisaccharide consisting of three alpha-D-glucose units connected via (1->3) linkages. Also known as alpha-nigerotriose.


A glucotriose that is D-glucopyranose in which the hydroxy groups at positions 2 and 6 have each been converted into the corresponding beta-D-glucopyranosyl derivatives.


A glucotriose consisting of three molecules of beta-D-glucopyranose attached in sequence by (1->2) and (1->6) glycosidic linkages.


A glucotriose consisting of beta-D-glucopyranose, alpha-D-glucopyranose and D-glucopyranose residues joined in sequence by (1->6) and (1->4) glycosidic bonds.


cellotriose

A glucotriose consisting of three


An alpha-D-Glcp-(1->3)-[alpha-D-Glcp-(1->4)]-D-Glcp in which the carbon bearing the anomeric hydroxy group has alpha- configuration.


A glucotriose consisting of two alpha-D-glucopyranose residues and a D-glucopyranose residue joined in sequence by (1->4) and (1->6) glycosidic bonds.


A glucotriose that is D-glucopyranose in which the hydroxy groups at positions 3 and 4 have each been converted to the corresponding alpha-D-glucopyranosyl derivative.


selaginose

A glycosyl glycoside derivative that is alpha-D-glucopyranosyl-(1->2)-alpha-D-glucopyranose in which the anomeric hydroxy group has been glycosylated by an alpha-D-glucopyranosyl group.


A alpha-D-Glcp-(1->4)-[alpha-D-Glcp-(1->6)]-D-Glcp which has alpha- configuration at the anomeric carbon of the non-terminal glucopyranose ring.


A glucotriose that is D-glucopyranose in which the hydroxy groups at positions 2 and 4 have been converted into the corresponding beta-D-glucopyranosyl and alpha-D-glucopyranosyl derivatives, respectively.


A glucotriose consisting of three alpha-D-glucopyranose residues joined in sequence by (1->6) and (1->2) glycosidic bonds.


beta-cellotriose

A cellotriose with a beta-configuration at the anomeric position.


A glucotriose consisting of two beta-D-glucopyranose residues and a D-glucopyranose residue joined in sequence by (1->6) and (1->3) glycosidic bonds.


A glucotriose consisting of two beta-D-glucopyranosyl residues and a D-glucopyranosyl residue joined in sequence by (1->4) and (1->3) glycosidic bonds.


A glucotriose consisting of alpha-D-glucopyranose, beta-D-glucopyranose and D-glucopyranose residues joined in sequence by (1->6) and (1->2) glycosidic bonds.


A glucotriose consisting of an alpha-D-glucopyranose residue and two beta-D-glucopyranose residues joined in sequence by (1->4) and (1->6) glycosidic bonds.


A glucotriose consisting of two alpha-D-glucopyranosyl residues and a D-glucopyranosyl residue joined in sequence by (1->3) and (1->2) glycosidic linkages.


alpha-cellotriose

A cellotriose with a alpha-configuration at the anomeric position.


A glucotriose composed of alpha-D-glucopyranose, alpha-D-glucopyranose and beta-D-glucofuranose residues joined in sequence by 1->6 glycosidic linkages.


18-hydroxylinoleic acid

An omega-hydroxy fatty acid that is linoleic acid in which one of the terminal methyl hydrogens has been replaced by a hydroxy group.


name: Uterine Corpus Spindle Smooth Muscle Tumor of Uncertain Malignant Potential

description: A smooth muscle tumor of uncertain malignant potential that arises from the uterine corpus and is composed of neoplastic spindle cells.


lipid A 4'-(2-aminoethyl diphosphate)

A member of the class of lipid As in which the 4' phosphate group of lipid A is replaced by 2-aminoethyl diphosphate.


poly(vinylcarbazole) polymer

A poly(vinyl) polymer, composed of poly(vinylcarbazole) macromolecules.


poly(alkylene) polymer

A poly(alkylene) polymer is a homopolymer, composed of poly(alkylene) macromolecules.


poly(acrylonitrile) polymer

A poly(vinyl) polymer, composed of poly(acrylonitrile) macromolecules.


poly(N-vinylimidazole) polymer

A poly(vinyl) polymer, composed of poly(N-vinylimidazole) macromolecules.


sodium polyanethol sulfonate polymer

A vinyl polymer, composed of sodium polyanethol sulfonate macromolecules.


polyethylene polymer

Polyethylene polymer is a poly(alkylene) polymer composed of polyethylene macromolecules.


poly(vinyl butyral) polymer

A poly(vinyl) polymer, composed of poly(vinyl butyral) macromolecules.


poly(vinyl methyl ether) polymer

A poly(ether) polymer, composed of poly(vinyl methyl ether) macromolecules.


vinyl polymer

A polymer, composed of vinyl polymer macromolecules.


poly(vinyl alcohol) polymer

Poly(vinyl alcohol) polymer is a homopolymer, which is composed of poly(vinyl alcohol) macromolecules.


polystyrene polymer

A poly(vinyl) polymer, composed of polystyrene macromolecules.


polyanethol sulfonic acid polymer

A vinyl polymer, composed of polyanethol sulfonic acid macromolecules.


pentacene

An acene that consists of five ortho-fused benzene rings in a rectilinear arrangement.


description: A rare serous cystadenocarcinoma that arises from the paratesticular structures.


D-threonine

An optically active form of threonine having D-configuration.


name: Fumarate Hydratase-Deficient Renal Cell Carcinoma

description: A rare, highly aggressive renal cell carcinoma caused by germline or (in a subset) somatic mutation of fumarate hydratase gene. It arises mostly in the setting of hereditary leiomyomatosis-renal cell carcinoma syndrome.


Acephalostomia

description: A congenital defect characterized by the absence of most or all of the head, with the presence of a mouth-like opening on the upper thorax.


An amino trisaccharide consisting of alpha-L-fucopyranosyl, beta-D-galactopyranosyl and 2-amino-2-deoxy-D-glucopyranose residues joined in sequence by (1->3) and (1->4) glycosidic bonds.


6-O-Acetyl-D-glucose in which the configuration at the anomeric centre is beta.


A monosaccharide derivative that is a D-glucose derivative having an acyl group at the O-6 position.


6-tuliposide B

A 6-O-acyl-D-glucose in which the 6-acyl group is specified as (3S)-3,4-dihydroxy-2-methylidenebutanoyl. A secondary metabolite with potent antibacterial activity, occurring specifically in tulip anthers.


glucose 6-monomycolate (C46)

A 6-O-acyl-D-glucose where the acyl group is 3-hydroxy-2-tetradecyldotriacontanoyl.


glucose 6-monomycolate

A 6-O-acyl-D-glucose that is the 6-O-[(20E)-2-docosyl-3-hydroxy-39-(nonadecan-2-yloxy)-39-oxononatriacont-20-enoyl] derivative of D-glucopyranose.


An amido thiophene-2-carboxylic acid derivative used as an inhibitor of HCV (Hepatitis C Virus) RNA polymerase.


Myositis, Proliferative

description: A rapidly growing, poorly circumscribed, mass-forming proliferation that arises from the skeletal muscle. It is characterized by the presence of spindle-shaped fibroblasts, round ganglion-like cells, myxoid to collagenous stroma formation, and high mitotic activity. It recurs only rarely following local excision and does not metastasize.


poly(p-phenylenevinylene) macromolecule

A macromolecule composed of alternating unsubstituted phenyl and para-vinyl groups.


diphenyleneiodonium chloride

An organic chloride salt having dibenziodolium as the counterion.


An 8-heptadecenal in which the double bond at position 8 adopts a cis-configuration.


A monounsaturated fatty aldehyde that is heptadecanal carrying a double bond at position 8.


An 8-heptadecenal in which the double bond at position 8 adopts a trans-configuration.


chondrochloren A

A monocarboxylic acid amide with formula C27H40ClNO7, that is produced by Chondromyces crocatus and exhibits antibiotic properties.


An indolylmethylglucosinolate that is the conjugate base of neoglucobrassicin, obtained by deprotonation of the sulfo group.


An alkenylglucosinolate that is the conjugate base of gluconapin.


A thia-alkylglucosinolate resulting from the removal of the proton of the hydrogen sulfate group of any omega-[(methylsulfanyl)alkyl]glucosinolic acid.


An alkylglucosinolate that is the conjugate base of glucocapparin.


An indolylmethylglucosinolate that is the conjugate base of 4-hydroxyglucobrassicin.


An alkylglucosinolate that is the conjugate base of 2-methylbutylglucosinolic acid.


A divalent inorganic anion obtained by removal of both protons from thiosulfuric acid.


A hydroxy-alkylglucosinolate that is 2-methylbutylglucosinolate which has been hydroxylated at the 2-position of the 2-methylbutyl chain.


glucosinolate

Water-soluble anionic substituted thioglucosides. Glucosinolates have a central C atom which is bonded via an S atom to a glycone group and via an N atom to a sulfonated oxime group, and which also carries a side-group. The side-chain and sulfate group have an anti stereochemical configuration across the C=N double bond.


aralkylglucosinolate

A glucosinolate having a aralkyl side chain.


A glucosinolate resulting from the removal of the proton from the oxime hydrogen sulfate group of glucoraphenin.


alkenylglucosinolate

A glucosinolate that is the conjugate base of alkenylglucosinolic acid.


An alkenylglucosinolate that is the conjugate base of sinigrin.


pentylglucosinolate

An alkylglucosinolate that is the conjugate base of pentylglucosinolic acid.


thia-alkylglucosinolate

A glucosinolate in which the side-chain consists of a thia-alkyl group.


A thia-alkylglucosinolate that has a 5-(methylsulfanyl)pentyl side chain attached to the sulfonated oxime group.


butylglucosinolate

An alkylglucosinolate that is the conjugate base of butylglucosinolic acid.


hydroxy-alkylglucosinolate

A glucosinolate in which the side-chain consists of a hydroxylated alkyl group.


An indolylmethylglucosinolate that is the conjugate base of 4-methoxyglucobrassicin, obtained by deprotonation of the sulfo group.


An hydroxy-alkylglucosinolate that is isobutylglucosinolate which has been hydroxylated at the 2-position of the isobutyl chain.


A glucosinolate that is glucobrassicanapin which has been hydroxylated at the 3-position of the hex-5-enimidoyl chain.


A indolylmethylglucosinolate that is the conjugate base of sulfoglucobrassicin.


isobutylglucosinolate

An alkylglucosinolate that is the conjugate base of isobutylglucosinolic acid.


An aralkylglucosinolate that is glucotropeolin in which the phenyl group is substituted at position 3 by a methoxy group.


A xi-progoitrin(1-) that is the conjugate base of epi-progoitrin.


hydroxy-alkenylglucosinolate

A glucosinolate in which the side-chain consists of a hydroxylated alkenyl group.


An indolylmethylglucosinolate that is the conjugate base of glucobrassicin, obtained by deprotonation of the sulfo group.


A aralkylglucosinolate that is the conjugate base of gluconasturtiin.


sulfonate

The sulfur oxoanion formed by deprotonation of sulfonic acid.


A glucosinolate resulting from the removal of a proton from the oxime hydrogen sulfate moiety of xi-progoitrin.


An alkylglucosinolate that is the conjugate base of glucocochlearin.


An alkenylglucosinolate that is the conjugate base of glucobrassicanapin.


A thia-alkylglucosinolate resulting from the removal of the proton of the hydrogen sulfate group of glucoiberverin.


A xi-progoitrin(1-) that is the conjugate base of progoitrin.


propylglucosinolate

An alkylglucosinolate that is the conjugate base of propylglucosinolic acid.


glycosinolate

An sulfur oxoanion resulting from the deprotonation of the hydroxy group attached to the sulfur of a glycosinolic acid.


A glucosinolate that is the  conjugate base of glucoraphanin.


An alkylglucosinolate resulting from the removal of the proton of the hydrogen sulfate group of any omega-[(methylsulfinyl)alkyl]glucosinolic acid.


A thia-alkylglucosinolate that has a 4-(methylsulfanyl)butyl side chain attached to the sulfonated oxime group.


A alkylglucosinolate that is the conjugate base of glucoputranjivin.


indolylmethylglucosinolate

A glucosinolate that is the conjugate base of indolylmethylglucosinolic acid.


Pancreatic Beta Cell Adenoma

description: An adenoma arising from the beta cells of the pancreas.  It produces insulin.


A dinitrotoluene that is toluene in which the hydrogens at positions 2 and 3 have been replaced by nitro groups.


Carcinoma of lower gum

description: A carcinoma of the oral cavity that arises from the lower gingiva.


Carcinoma of upper gum

description: A carcinoma of the oral cavity that arises from the upper gingiva.


Gingival Spindle Cell Carcinoma

description: A poorly differentiated squamous cell carcinoma that arises from the gingiva. It is characterized by the presence of malignant pleomorphic spindle cells.


Gingival Squamous Cell Carcinoma

description: A squamous cell carcinoma that arises from the gingival mucosa. It presents as an ulcerated lesion or exophytic mass. The prognosis is usually poor.


Gingival Angiofibroma

description: A benign neoplasm arising from the fibrous soft tissues of the gingiva. It is characterized by the presence of spindle-shaped fibroblasts and numerous dilated vascular channels.


squamous cell carcinoma of lower gum

description: A squamous cell carcinoma of the oral cavity that arises from the lower gingiva.


carcinoma of gingiva

description: A carcinoma of the oral cavity that arises from the upper or lower gingiva.


squamous cell carcinoma of upper gum

description: A squamous cell carcinoma of the oral cavity that arises from the upper gingiva.